With the alarming rise of antibiotic resistance, clinical professionals are called upon to manage antibiotic therapies using the most relevant and recent clinical and laboratory data. To this end, antimicrobial stewardship (AMS) programs aim to reduce unnecessary or suboptimal use of antibiotics while maximizing outcomes for the patient. For AMS programs to succeed, the active participation of clinical professionals at all levels of patient care is required. Although programs exist to train established clinicians in AMS, there is a paucity of literature on how and when to integrate AMS concepts and skills in pre-clinical and clinical coursework. Here, we discuss the crucial microbiology concepts and proficiencies that are necessary for building and supporting an AMS program. We provide recommendations for key points to include in clinical curricula in order to develop the necessary microbiology interpretation skills to participate in AMS. The influence of AMS programs on local organism susceptibility patterns is emphasized. The importance of antibiograms, rapid diagnostic testing and the practical interpretations of microbiology laboratory reporting are discussed in regard to prioritization in clinical curricula. We also review the current literature on instructional strategies for introducing AMS into clinical programs, and propose concepts that should be included in didactic coursework in order to provide a foundation for AMS education.
INTRODUCTION
Microbial resistance is one of the greatest public health threats our population faces today. An overwhelming amount of evidence attributes the causal behavior of widespread misuse and overuse of antimicrobial agents as the main driver of global microbial resistance (Michael, Dominey-Howes and Labbate 2014) . As the rate of resistance continues to exceed that of new drug development, judicious use of currently available antimicrobial agents is of utmost importance. Antimicrobial stewardship (AMS) is a blanket term used to describe a variety of interventions that facilitate appropriate use of antimicrobial agents to improve clinical care for the patient while reducing collateral damage of emerging drug resistance. Core principles include assessment of need for antimicrobial therapy, agent selection, dose, administration interval, duration of therapy and therapeutic drug monitoring for certain antimicrobial agents.
Sir Alexander Fleming himself recognized the significance of AMS with his forward-thinking statement in 1945, 'The microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out. . . in such cases the thoughtless person playing with penicillin is morally responsible for the death of the man who finally succumbs to infection with the penicillin-resistant organism. I hope this evil can be averted'. While this concept is not new, proper evidence-based guidance to thwart microbial resistance has received large-scale attention only throughout the past decade. The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America first provided practice guidelines for AMS in 2007, prior to a recent 2016 update (Dellit et al. 2007; Barlam et al. 2016) . These guidelines established a foundation for the composition of modern AMS programs. Collaborative and multidisciplinary working relationships between a physician and pharmacist with infectious diseases training, a clinical microbiologist and an infection control practitioner are vital components (Dellit et al. 2007; Dik et al. 2016) . In veterinary medicine, the need for AMS is also recognized, although official guidelines are more challenging to clarify (Weese et al. 2015) . Nevertheless, the American College of Veterinary Internal Medicine has issued a consensus statement that supports the use of bacterial culture data for diagnosis and choice of therapy and highlights circumstances where antimicrobial use could be limited.
Countries such as France, Germany, Ireland, Spain, the Netherlands and the UK have established complementary recommendations guiding stewardship initiatives in their respective countries (European Centre for Disease Prevention and Control 2016). Recently, the United States Centers for Disease Control and Prevention (CDC) and European Centre for Disease Prevention and Control have released structure and process indicators for hospital AMS programs through a Transatlantic Task Force on Antimicrobial Resistance (Transatlantic Task Force on Antimicrobial Resistance 2015). Other notable global efforts include implementation and prospective reporting of an antimicrobial resistance strategic framework in South Africa (Federation of Infectious Diseases Societies of Southern Africa 2016) and recent advances of AMS strategy and AMS mandatory incorporation for hospital accreditation in Australia (Cairns et al. 2015) . Furthermore, India has recently passed the Chennai Declaration, a 5-year plan to address antimicrobial resistance by reducing and restricting both inpatient and outpatient use of antimicrobial agents (Chennai Declaration Team 2014) . Although the majority of AMS initiatives target the inpatient setting, many notable efforts have been recently made in the outpatient setting where the majority of antimicrobials are prescribed (Drekonja et al. 2015) .
While AMS is finally gathering attention worthy of its global importance, these documents provide guidance exclusively for the clinician rather than the classroom educator. A prominent question in infectious diseases didactic education is how, when and to what extent do we prepare the next generation of health care providers to combat antimicrobial resistance? In this review, we describe the principle concepts that are necessary for engaging in AMS, and discuss how undergraduate and professional-level microbiology courses could serve as a foundation for training clinical professionals in AMS practices.
CURRENT STATUS OF AMS EDUCATION
The CDC estimates that only 39.2% of hospitals in the United States have AMS programs as of 2014, with the goal implementation in 100% of hospitals by 2020 (Centers for Disease Control and Prevention 2016a). Given the pervasive need for new stewardship programs, the question arises of how to best prepare medical professionals for participating in stewardship. Most current educational efforts focus at the institutional level, where pharmacists and physicians are called upon to design and implement AMS programs. Ideally, AMS programs would be anchored by a physician and pharmacist with advanced ID training (Dellit et al. 2007 ). However, in many instances, clinicians without specialized ID training are called upon to fulfill these roles. In order to produce clinical professionals who are prepared to sustain future AMS programs, the curricula of medical, pharmacy, nursing and veterinary programs would need to consider how to integrate significant AMS concepts into their coursework. Indeed, current ISDA guidelines also recommend that the fundamental principles of antibiotic stewardship should be integrated into preclinical medical curricula (Barlam et al. 2016) .
Although there is a widely recognized need to train clinical professionals to participate in AMS programs, there is little literature regarding approaches for AMS education. A recent survey of undergraduate health care and veterinary programs in the UK found that many programs include components of AMS (80.7% of respondents), but that few programs (36.3%) addressed all of the key topics recommended by current UK stewardship policies (Castro-Sanchez et al. 2016) . However, clinical students recognize the need to engage in AMS, and appreciate that their clinical decisions can contribute to development of resistance (Dyar et al. 2014 ). Yet in a survey of US medical students, more than two-thirds of respondents reported that they did not feel well prepared to streamline or de-escalate antibiotic therapy, which is a key concept in AMS (Abbo et al. 2013) . For doctor of pharmacy (PharmD) programs, there is little guidance for AMS incorporation into the standard curriculum. Student performance on AMS-related questions varies widely by school, suggesting that the approaches to AMS education are likely disparate across PharmD programs (Justo et al. 2014) . Reports on elective courses for AMS suggest that student understanding of AMS principles can be improved in smaller settings with active learning components, but such offerings are limited to specific programs (Falcione and Meyer 2014; Gauthier, Sherman and Unger 2015) .
As pharmacy educators, our goal is to prepare students to engage in AMS upon completion of their degree. Indeed, in a recently proposed model for AMS education in PharmD curricula, AMS principles were integrated at all stages. A greater emphasis of AMS education was suggested during advanced pharmacy practice experience where students are introduced to patient care under the guidance of a preceptor, similar to an apprenticeship, in their final year of coursework (Chahine, El-Lababidi and Sourial 2015) . Although we recognize that students require additional training upon graduation to become proficient in AMS, there are foundational concepts that can be imparted during their coursework. Pharmacy programs vary as to whether microbiology is required as a prerequisite for entry into the professional phase of the program. For those programs that do not require microbiology, basic principles of infectious disease and bacteriology also must be addressed within the professional phase, before more advanced AMS topics can be discussed.
Regardless of whether a traditional microbiology course is included in the curriculum, PharmD students must first master an understanding of the differences between Gram-positive and Gram-negative microorganisms and major classes of bacterial pathogens. This content is typically addressed in many undergraduate microbiology courses, but may require further depth in terms of medically relevant pathogens. Additionally, an understanding of how bacterial resistance develops and spreads amongst bacteria allows students to appreciate how readily antibiotic resistance can occur. As future pharmacists, PharmD students must also master the different classes of antibiotics and the mechanisms of action of each. This includes an understanding of the pharmacokinetics and pharmacodynamics (PK/PD) for relevant antibiotics, which informs the drug concentrations that can be expected in bodily fluids from a particular dose (PK) and the expected effects resulting from a particular concentration (PD). Students must become familiar with common microbiology culture reports, including the interpretations of 'susceptible', 'intermediate' and 'resistant' classifications for antibiotic testing and the utility of minimum inhibitory concentrations (MICs). With such a foundation in medically relevant bacteria and current antibiotics, students can begin to develop an understanding of 'bug-drug' coverage, where the selection of appropriate antibiotic therapy is made based on the likely pathogens involved in a given condition. With such groundwork, students are in a position to practice the skills necessary for AMS. A recent review on AMS initiatives suggests that medical students must engage in problem-based learning and interactive discussions in order to integrate their AMS skills (Pulcini and Gyssens 2013) . Similarly, the available literature for AMS education in pharmacy programs demonstrates that senior students perform well with case-based, active-learning approached in elective settings (Falcione and Meyer 2014; Gauthier, Sherman and Unger 2015) . Together, these findings suggest that the foundations for AMS can begin in a didactic setting, but must ultimately shift to a more problem-based approach for the students to hone their clinical decision-making skills.
For clinical professional students, we propose that there are four main AMS principles, as they relate to microbiology education, that should be addressed prior to graduation. These principles can be aligned within an outcome-based teaching approach. The importance of using an outcome-based approach is necessary considering the heterogeneity of global need and focus of AMS. This method has been described within various forms of medical education framework (Davenport, Davey and Ker 2005; Public Health England 2016) . Here, we describe the rationale for each principle and examples of each, and offer key points that guide the learning outcomes for AMS education.
OUTCOME 1. REDUCING THE SPREAD OF ANTIMICROBIAL RESISTANCE: IMPACT OF AMS INITIATIVES ON ORGANISM SUSCEPTIBILITY PATTERNS
Core interventions for AMS initiatives in health care institutions target inappropriate use of broad-spectrum antimicrobials. They typically include either prospective audit or formulary restriction processes or a combination of the two (Barlam et al. 2016) . Performing prospective audits provides ongoing assessment of existing antimicrobial orders throughout an institution. Audits ideally occur on a daily basis, but, depending on resources, can also be effective when performed two or three times weekly. When therapy modification or discontinuation is deemed necessary by AMS staff, verbal recommendations are then made to the prescriber for alternative treatment plans while explaining rationale for the proposed changes. In contrast, formulary restriction processes occur prior to order verification. An AMS clinician will first be notified once an order is placed for a broadspectrum antimicrobial agent. The selection is then either approved or modified by the AMS service, depending on patient need, prior to medication verification and administration.
A point of emphasis that cannot be underestimated is that practitioners must establish professional rapport for these approaches to remain effective. Many clinicians can be intimidated by AMS programs due to concerns regarding loss of prescriptive autonomy. Stewardship implementation should project a collaborative approach and be performed in such a way to limit these concerns. These approaches should also be implemented systematically and become a regular, understood part of clinical practice. The 'Start Smart, Then Focus' strategy and core elements of AMS provided by the CDC advocate for consistent evaluation of treatment decisions upon initiation and longitudinal assessment at strategic treatment time points (Public Health England 2015, Centers for Disease Control and Prevention 2016b). The end result, if performed successfully, is an overall reduction in inappropriate antimicrobial utilization.
The ultimate goal of these efforts is to positively influence local ecology. Unfortunately, a particularly narrow focus of restriction can also yield unanticipated consequences. For example, a hallmark clinical study implemented absolute restriction of cephalosporin antibiotics while using carbapenem antibiotics as a substitute. The study met its endpoint by significantly reducing cephalosporin-resistant Klebsiella spp. only at the expense of causing a substantial increase in Pseudomonas aeruginosa resistance to carbapenems (Rahal et al. 1998) . Hence, shifting antimicrobial use and subsequent resistance burden can be likened to squeezing a balloon. Exclusive restriction of one agent in favor of another causes a compensatory rise in resistance of the second agent (Burke 1998) . It is important to convey students lessons learned from this phenomenon.
Key points of emphasis in clinical education:
1. Core interventions of AMS include prospective audit with feedback and formulary restriction, or a combination of both approaches. 2. AMS practitioners must form collaborative, interdisciplinary relationships to enhance AMS initiative success. 3. Stewardship initiatives positively impact antimicrobial susceptibility rates only when enacting comprehensive efforts to reduce total antimicrobial use burden across multiple medication classes.
OUTCOME 2. APPROPRIATE SELECTION AND PRESCRIBING OF ANTIMICROBIALS: ROLE OF ANTIBIOGRAMS TO SUPPLEMENT EVIDENCE-BASED MEDICINE INITIATIVES
Antibiograms provide guidance on local antimicrobial susceptibility patterns, and are often used in inpatient settings at the institutional level. These documents provide drug/bug coverage results from a compiled report of susceptibility data generated by the microbiology laboratory over a specific time period (Fig. 1) . The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing provide guidance for susceptibility testing and interpretation for most pathogenic organisms (Clinical and Laboratory Standards Institute 2014; European Committee on Antimicrobial Susceptibility Testing 2016). These organizations determine clinical breakpoints, which establish MIC limits for pathogens susceptible or resistant to a certain antibiotic. These breakpoints are implemented when cultures are processed in everyday patient care situations. Likewise, this information is used for culture reporting which advises on optimal patient treatment options.
While clinical guidelines published in the primary literature give guidance for initial selection of antimicrobial regimen for disease states, antibiogram data describing local Numbers displayed in cells where organism type and antibiotic intersect represent percent susceptibility. For instance, in the figure, ceftriaxone displays 91% susceptibility for Streptococcus pneumoniae isolates. Unique isolates from patient specimens used for aggregate data. Acceptable minimum number of isolates for each drug/bug combination to be reported is typically 30 isolates. Depending on institutional resources and need, antibiograms can be created for specific hospital units (i.e. intensive care unit versus general hospital floor), culture type (i.e. urine cultures versus all other culture sites) or for combination drug susceptibilities (i.e. Pseudomonas aeruginosa susceptibility for cefepime plus tobramycin combination). susceptibility patterns should also be taken into consideration when making drug therapy decisions. For example, the antibiotic sulfamethoxazole/trimethoprim is recommended by IDSA guidelines for front-line use in acute, uncomplicated urinary tract infections (UTIs) only if resistance is <20% (i.e. susceptibility against common UTI-causing organisms Escherichia coli and Klebsiella spp. is ≥80% on antibiogram findings). The following example also supports the analysis of culture sitespecific antibiograms since data exclusively from urine cultures would more accurately depict UTI-specific susceptibility rates.
A clinical controversy exists regarding whether or not to use combination antibiotic agents to target Gram-negative pathogens for medical conditions such as hospital-acquired pneumonia and sepsis. Combination therapy may or may not provide better coverage than a single agent, and overuse of antibiotics and subsequent resistance development remain concerns. Although current recommendations focus on the assessment of risk factors for MDR pathogens for these treatment decisions, innovative approaches to antibiogram data can also be helpful. Combination antibiograms can describe local susceptibility rates of two or more agents when targeting a pathogen. For example, a classic antibiogram might report individual Pseudomonas aeruginosa susceptibility rates for cefepime (88%) and tobramycin (78%), while a combination antibiogram could indicate 95% susceptibility for the combination of cefepime plus tobramycin. These data can help clinicians make betterinformed decisions on the perceived benefit of antibiotic double coverage.
1. Both evidence-based guidelines and local antibiogram data should be used to yield the best possible chance of antimicrobial treatment success. 2. Antibiogram information can help provide data to support clinically controversial treatment decisions, such as double coverage of Gram-negative pathogens.
OUTCOME 3. TIMELY USE OF ANTIMICROBIALS TO IMPROVE TREATMENT OUTCOMES: RAPID DIAGNOSTIC TESTING
Various methods of rapid diagnostic testing are available. The goal for these testing methods is to provide qualitative culture data earlier in the disease process to provide an opportunity for timely selection of optimal, targeted antimicrobial regimens. Most of these testing methods (i.e. polymerase chain reaction, peptide nucleic acid hybridization, culture colony test) provide a genetic basis for a presumptive identification of an organism following in as little as 1 h or less following organism growth. This compares with conventional methods that typically take 48-72 h. Further quantitative data for drug susceptibility must subsequently be run on a conventional antimicrobial susceptibility testing platform.
In clinical practice, time to appropriate antimicrobial therapy is an important concept that can influence mortality in patients with serious systemic infections. Likewise, overtreatment when unnecessary can augment antimicrobial resistance patterns. Rapid diagnostic testing is often a key component that allows for antibiotic de-escalation, a principle that describes switching from a broad-spectrum antibiotic to a more narrow-spectrum antibiotic to target the pathogen identified. For instance, a rapid diagnostic test is performed for a patient who has Gram-positive cocci in clusters growing from a blood culture. The test reveals a negative result for penicillin binding protein 2A (PBP2a), a resistance determinant for methicillin-resistant Staphylococcus aureus (MRSA). The patient can then undergo de-escalation from their current broad-spectrum antibiotic, vancomycin, to an antistaphylococcal penicillin such as nafcillin, which also has better activity and treatment outcomes for methicillin-susceptible S. aureus.
1. Rapid diagnostic testing provides timely and useful microbiological information to make informed treatment decisions earlier in the course of disease to positively influence treatment outcomes. 2. Antibiotic de-escalation provides a means for streamlining therapy from a broad-to narrow-antibiotic spectrum to more effectively treat an infection while limiting broad-spectrum antimicrobial exposure
OUTCOME 4. ACCURATE INTERPRETATION OF MICROBIOLOGY LABORATORY REPORTING: PRACTICAL KNOWLEDGE TO MAKE CLINICAL TREATMENT DECISIONS
Whenever possible, cultures from various sites of the body should always be obtained prior to initiation of antimicrobial therapy. Prior antimicrobial therapy can reduce culture yield and accuracy. This underlying concept is important, considering empirical antimicrobial therapy (typically broad spectrum to cover a multitude of pathogens for a specific infectious disease) must be implemented prior to culture results. If culture results are not obtained or processed correctly, this increases the need for continuation of broad-spectrum therapy and, in turn, counteracts AMS principles. Collaboration between microbiology departments and AMS practitioners must take place to ensure that the proper antimicrobial susceptibilities are illustrated on culture reports. Only agents available to clinicians, often on an institutional formulary list, should be displayed. Furthermore, results of certain broadspectrum antimicrobial agents should be 'suppressed' within disseminated microbiology reports to support AMS principles. For instance, carbapenem antibiotic susceptibility results should not be reported for Streptococcus pyogenes, which is reliably susceptible to regular penicillin. The AMS principle of 'out of sight, out of mind' is key for reducing unnecessary use of broadspectrum agents.
Commercial automated microdilution systems perform the large majority of antimicrobial susceptibility testing in the United States. Common systems include Vitek (BioMerieux, Marcy-IEtoile, France), Microscan (Beckman Coulter, Brea, CA, USA) and Phoenix (Becton Dickinson, Franklin Lakes, NJ, USA). These systems preferentially reduce laboratory time and labor, while yielding faster susceptibility reporting for clinical interpretation. While rates of major errors are low for these testing methods (<5%), conventional quality control guidance suggests acceptable error as plus or minus one 2-fold dilution. Clinical data indicate that minor changes in organism MIC may predict treatment failure. For example, guidelines for the treatment of MRSA recommend alternative antibiotic therapy for MRSA isolates with a vancomycin MIC ≥ 2 (Liu et al. 2011) . Patients commonly display MRSA MICs = 1 for vancomycin in clinical practice. Therefore, a prudent clinician must understand that acceptable error dictates the isolate may in fact have an MIC = 0.5 to 2, both of which would be treated very differently. The key is proper assessment of patient clinical progress, particularly for MIC values from microbiology reports that approach the susceptibility breakpoint.
Many non-sterile sites of the body exist, most notably the upper respiratory tract, gastrointestinal tract and genitourinary tract. Analysis of cultures that are ordered within these sites of the body should take into account growth of normal flora (colonization) as well as the potential presence of infectious pathogens. In addition, sometimes cultures from sterile sites of the body can be contaminated due to breaks in sterile technique. Skillful clinical interpretation must be performed to differentiate positive culture results that must be treated and those where antimicrobial treatment is not warranted.
Various patient care scenarios exist for which microbiological findings do not require treatment intervention. Common scenarios include growth of coagulase-negative Staphylococci in blood cultures (commonly skin flora acquired due to inconsistent venipuncture technique) or patients with asymptomatic presentation despite positive urine culture growth, also known as asymptomatic bacteriuria. These organisms only represent true pathogens in a limited number of patient-specific circumstances. Therefore, antibiotic avoidance in these common circumstances can curb a large percentage of unnecessary antimicrobial use. Stopping antibiotic exposure before it starts can significantly impact AMS efforts.
Just as the potential for false-positive cultures to exist, falsenegative cultures can also complicate clinical scenarios. Various fastidious organisms such as Haemophilus influenzae and mycobacteria take significant time for culture growth. Likewise, fungal pathogens such as yeasts display a relatively low culture yield (≤50%) that rival a coin flip. Often, anaerobes from a wound culture are difficult to grow in the lab and identify, not to mention when organisms such as Proteus mirabilis can swarm the plate to make identification incredibly difficult. Fastidious organisms require special media, biomarkers can help with suspicion for fungal pathogens and sometimes the very smell of a wound is the best indicator for anaerobe presence. Recognition of these scenarios can ensure proper treatment necessary for optimal patient outcomes.
1. AMS practitioners should collaborate with microbiology staff to selectively report only antimicrobial susceptibilities that are prudent for clinical use. 2. Appropriate clinical correlation of MIC values is necessary as small changes in MIC acceptable error can cause significant clinical implications. 3. All positive cultures do not require treatment, particularly if they represent normal flora colonization or contamination from a non-sterile source. 4. In the absence of culture data for patients displaying signs and symptoms of infection, fastidious organisms should be suspected as a possible cause of infection with implementation of treatment accordingly.
CONCLUSIONS
Antibiotic stewardship is moving target, which offers a challenge for pre-medical and medical education. National, regional and institutional differences yield unique antibiograms. Breakpoints are continually adjusted to account for changes in susceptibility. Individual patient and institutional considerations also influence clinical decision making. With such an array of variables, we propose that it is important for students in the clinical professions to begin with a strong foundation in microbiology and to develop their clinical intuition early in their preclinical education. As ID educators, we propose that undergraduate microbiology courses with a laboratory component should be a prerequisite for all health care programs. Without a solid understanding of the diversity and pathogenesis of microorganisms, mechanisms of antibiotic resistance and basic laboratory testing strategies, building a clinical understanding of how to choose antimicrobial therapy can be challenging for a student. By building a solid foundation in undergraduate coursework, clinical professional students will be better prepared to master the more challenging clinical ID literature and the pitfalls of laboratory testing, both of which are critical skills for participating in AMS.
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